Analyst Conference Summaries |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Aprea Therapeutics
|
2024 | |||
Aprea Therapeutics Q1 2024 |
Aprea Therapeutics Q1 2024 |
||
May 14, 2024 | Aug. 12, 2024 | ||
2023 | |||
Aprea Therapeutics Q1 2023 |
Aprea Therapeutics Q2 2023 |
Aprea Therapeutics Q3 2023 |
Aprea Therapeutics Q4 2023 |
May 15, 2023 | Aug. 10, 2023 | Nov. 9, 2023 | Mar. 26, 2024 |
2022 | |||
Aprea Therapeutics Q1 2022 |
Aprea Therapeutics Q2 2022 Press Release |
Aprea Therapeutics Q3 2022 Press Release |
Aprea Therapeutics Q4 2022 Press Release |
May 16, 2022 | August 11, 2022 | Nov. 9, 2022 | March 30, 2023 |
2021 | |||
Aprea Therapeutics Q1 2021 release |
Aprea Therapeutics Q2 2021 release |
Aprea Therapeutics Q3 2021 summary |
Aprea Therapeutics Q4 2021 summary |
May 6, 2021 | Aug. 12, 2021 | Nov. 8, 2021 | March 15, 2022 |
2020 | |||
Aprea Therapeutics Q1 2020 release |
Aprea Therapeutics Q2 2020 release |
Aprea Therapeutics Q3 2020 release |
Aprea Therapeutics Q4 2020 release |
May 15, 2020 | Aug. 11, 2020 | Nov. 5, 2020 | March 16, 2021 |
Aprea Therapeutics (APRE) is a clinical-stage biotechnology company specializing in therapies for cancers with TP53 mutations.
More Analyst Conference Pages:
AGEN |
AGIO |
ALLO |
ALNY |
AMAT |
AMGN |
BIIB |
BMY |
CDTX |
CLDX |
FATE |
GILD |
GLYC |
ILMN |
INO |
MCHP |
MRNA |
PLX |
REGN |
RNA |
SAGE |
SGEN |
SYRS |
TSVT |
VRTX |
VSTM |
WBA |
Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.
Copyright 2023 William P. Meyers